International Journal of Clinical Pediatric Dentistry

Register      Login

VOLUME 16 , ISSUE 6 ( November-December, 2023 ) > List of Articles

ORIGINAL RESEARCH

Comparative Evaluation of the Treatment Outcomes of Pulpotomy in Primary Molars Using Mineral Trioxide Aggregate and 3Mixtatin: A Randomized Clinical Trial

Anam Mushtaq, Tanu Nangia, Mousumi Goswami

Keywords : Mineral trioxide aggregate, Primary molars, Pulpotomy, Statin

Citation Information : Mushtaq A, Nangia T, Goswami M. Comparative Evaluation of the Treatment Outcomes of Pulpotomy in Primary Molars Using Mineral Trioxide Aggregate and 3Mixtatin: A Randomized Clinical Trial. Int J Clin Pediatr Dent 2023; 16 (6):810-815.

DOI: 10.5005/jp-journals-10005-2720

License: CC BY-NC 4.0

Published Online: 01-02-2024

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

Objective: To evaluate and compare the efficacy of 3Mixtatin and mineral trioxide aggregate (MTA) for pulpotomy in primary teeth by assessment of pre- and postoperative clinical and radiographic data. Materials and methods: In this randomized clinical trial, 50 primary molars from 48 healthy children aged 3–8 years were randomly allocated into two groups. Deep dentinal caries approaching pulp in primary teeth were treated by pulpotomy using MTA and 3Mixtatin. Over the intervening period, restoration was done using glass ionomer cement (GIC) and composite, followed by stainless steel crown. Clinical and radiographic examinations were conducted at 3, 6, and 12 months after treatment. The data were compared using Chi-squared test at a significance level of 0.05. Results: A total of 39 patients were available for follow-up study. By the end of 12 months, the overall success rates were 95.5% in MTA and 91.3% in 3Mixtatin. No statistically significant difference was found among the outcomes of MTA and 3Mixtatin groups (p > 0.05). Conclusion: Radiographic and clinical outcomes in MTA and 3Mixtatin group in this study show 3Mixtatin as a suitable alternative for pulpotomy medicament in primary teeth.


HTML PDF Share
  1. Al-Dlaigan YH. Pulpotomy medicaments used in deciduous dentition: an update. J Contemp Dent Pract 2015;16(6):486–503. DOI: 10.5005/jp-journals-10024-1711
  2. Caruso S, Dinoi T, Marzo G, et al. Clinical and radiographic evaluation of biodentine versus calcium hydroxide in primary teeth pulpotomies: a retrospective study. BMC Oral Health 2018;18(1):54. DOI: 10.1186/s12903-018-0522-6
  3. Markovic D, Zivojinovic V, Vucetic M. Evaluation of three pulpotomy medicaments in primary teeth. Eur J Paediatr Dent 2005;6(3):133–138.
  4. Fuks AB. Vital pulp therapy with new materials for primary teeth: new directions and treatment perspectives. Pediatr Dent 2008;30(3):211–219.
  5. Chandrashekhar S, Shashidhar J. Formocresol, still a controversial material for pulpotomy: a critical literature review. J Restor Dent 2014;2:114–124. DOI: 10.4103/2321-4619.143594
  6. Torabinejad M, Chivian N. Clinical applications of mineral trioxide aggregate. J Endod 1999;25(3):197–205. DOI: 10.1016/S0099-2399(99)80142-3
  7. Holan G, Eidelman E, Fuks AB. Long-term evaluation of pulpotomy in primary molars using mineral trioxide aggregate or formocresol. Pediatr Dent 2005;27(2):129–136.
  8. Asl Aminabadi N, Satrab S, Najafpour E, et al. A randomized trial of direct pulp capping in primary molars using MTA compared to 3Mixtatin: a novel pulp capping biomaterial. Int J Paediatr Dent 2016;26(4):281–290. DOI: 10.1111/ipd.12196
  9. Aminabadi NA, Huang B, Samiei M, et al. A randomized trial using 3Mixtatin compared to MTA in primary molars with inflammatory root resorption: a novel endodontic biomaterial. J Clin Pediatr Dent 2016;40(2):95–102. DOI: 10.17796/1053-4628-40.2.95
  10. Jamali Z, Alavi V, Najafpour E, et al. Randomized controlled trial of pulpotomy in primary molars using MTA and formocresol compared to 3Mixtatin: a novel biomaterial. J Clin Pediatr Dent 2018;42(5):361–366. DOI: 10.17796/1053-4625-42.5.7
  11. Olatosi OO, Sote EO, Orenuga OO. Effect of mineral trioxide aggregate and formocresol pulpotomy on vital primary teeth: a clinical and radiographic study. Niger J Clin Pract 2015;18(2):292–296. DOI: 10.4103/1119-3077.151071
  12. Ng FK, Messer LB. Mineral trioxide aggregate as a pulpotomy medicament: an evidence-based assessment. Eur Arch Paediatr Dent 2008;9(2):58–73. DOI: 10.1007/BF03262612
  13. Whitaker EJ, Alshammari A. Bacteriostatic effect of simvastatin on selected oral streptococci in vitro. Contemp Clin Dent 2017;8(1):59–63. DOI: 10.4103/ccd.ccd_848_16
  14. Doneria D, Thakur S, Singhal P, et al. Comparative evaluation of clinical and radiological success of zinc oxide-ozonated oil, modified 3mix-mp antibiotic paste, and vitapex as treatment options in primary molars requiring pulpectomy: an in vivo study. J Indian Soc Pedod Prev Dent 2017;35(4):346–352. DOI: 10.4103/JISPPD.JISPPD_359_16
  15. Takushige T, Hoshino E, Ando H. Endodontic retreatment using 3Mix-MP without removal of previous root canal obturation. J LSTR Ther 2009;8:3–7.
  16. Guelmann M, Fair J, Bimstein E. Permanent versus temporary restorations after emergency pulpotomies in primary molars. Pediatr Dent 2005;27(6):478–481.
  17. Hutcheson C, Seale NS, McWhorter A, et al. Multi-surface composite vs stainless steel crown restorations after mineral trioxide aggregate pulpotomy: a randomized controlled trial. Pediatr Dent 2012;34(7):460–467.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.